Avalo Therapeutics AVTX Cash & Equivalents
Cash & Equivalents at other companies
Other financials
Where this comes from
Reported directly by Avalo Therapeutics in its filing.
Tagged under the XBRL concept us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents.
The official record: Avalo Therapeutics’s 10-Q, filed May 13, 2026, on SEC EDGAR. View the filing →
Ask your AI about Avalo Therapeutics's cash & equivalents.
Connect your AI assistant and compare it to peers, right in your chat.
Connect your AI
Claude
Questions, answered.
- What is Avalo Therapeutics's cash & equivalents?
- Avalo Therapeutics (AVTX) reported cash & equivalents of $25.32M in Q1 2026.
- How has Avalo Therapeutics's cash & equivalents changed year-over-year?
- Avalo Therapeutics's cash & equivalents decreased by 79.8% year-over-year, from $125.24M to $25.32M.
- What is the long-term trend for Avalo Therapeutics's cash & equivalents?
- Over 5 years (2020 to 2025), Avalo Therapeutics's cash & equivalents has grown at a -3.4% compound annual growth rate (CAGR), from $19.11M to $16.11M.
- What does cash & equivalents mean?
- Cash on hand plus highly liquid investments with maturities of three months or less at purchase — treasury bills, money market funds, and commercial paper.